Synaptic degeneration in Alzheimer disease

M Tzioras, RI McGeachan, CS Durrant… - Nature Reviews …, 2023 - nature.com
Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders

A Samidurai, L Xi, A Das… - Annual review of …, 2023 - annualreviews.org
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …

Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: from physiology to Alzheimer's disease

MR Tropea, W Gulisano, V Vacanti, O Arancio… - Free Radical Biology …, 2022 - Elsevier
The nitric oxide (NO)/cGMP pathway has been extensively studied for its pivotal role in
synaptic plasticity and memory processes, resulting in an increase of cAMP response …

Tau toxicity in neurodegeneration

SY Liang, ZT Wang, L Tan, JT Yu - Molecular Neurobiology, 2022 - Springer
Tau is a microtubule-associated protein widely distributed in the central nervous system
(CNS). The main function of tau is to promote the assembly of microtubules and stabilize …

Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease

E Zuccarello, E Acquarone, E Calcagno… - Biochemical …, 2020 - Elsevier
Nitric oxide (NO) is a gaseous molecule that plays a multifactorial role in several cellular
processes. In the central nervous system, the NO dual nature in neuroprotection and …

CREB: a multifaceted target for Alzheimer's disease

VK Sharma, TG Singh - Current Alzheimer Research, 2020 - ingentaconnect.com
Alzheimer's disease (AD) is a persistent neuropathological stipulation manifested in the form
of neuronal/synapse demise, the formation of senile plaques, hyperphosphorylated tau …

Neuroprotective Effect of NO-Delivery Dinitrosyl Iron Complexes (DNICs) on Amyloid Pathology in the Alzheimer's Disease Cell Model

WH Chuang, YT Chou, YH Chen, TH Kuo… - ACS Chemical …, 2023 - ACS Publications
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive
impairment, memory loss, and behavioral deficits. β-amyloid1–42 (Aβ1–42) aggregation is a …

Therapeutic potential of phosphodiesterase inhibitors against neurodegeneration: The perspective of the medicinal chemist

G Ribaudo, A Ongaro, G Zagotto, M Memo… - ACS chemical …, 2020 - ACS Publications
Increasing human life expectancy prompts the development of novel remedies for cognitive
decline: 44 million people worldwide are affected by dementia, and this number is predicted …

Synaptic mitochondria: an early target of amyloid-β and tau in Alzheimer's disease

AK Torres, C Jara, HS Park-Kang… - Journal of …, 2021 - content.iospress.com
Alzheimer's disease (AD) is characterized by cognitive impairment and the presence of
neurofibrillary tangles and senile plaques in the brain. Neurofibrillary tangles are composed …

Differential microRNA expression analyses across two brain regions in Alzheimer's disease

V Dobricic, M Schilling, J Schulz, LS Zhu… - Translational …, 2022 - nature.com
Dysregulation of microRNAs (miRNAs) is involved in the pathogenesis of
neurodegenerative diseases, including Alzheimer's disease (AD). Hitherto, sample sizes …